GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Caplin Point Laboratories Ltd (BOM:524742) » Definitions » Net Cash per Share

Caplin Point Laboratories (BOM:524742) Net Cash per Share : ₹59.86 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Caplin Point Laboratories Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Caplin Point Laboratories's Net Cash per Share for the quarter that ended in Mar. 2024 was ₹59.86.

The historical rank and industry rank for Caplin Point Laboratories's Net Cash per Share or its related term are showing as below:

BOM:524742' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 10.95   Med: 17.23   Max: 28.8
Current: 21.76

During the past 13 years, the highest Price-to-Net-Cash Ratio of Caplin Point Laboratories was 28.80. The lowest was 10.95. And the median was 17.23.

BOM:524742's Price-to-Net-Cash is ranked worse than
76.31% of 249 companies
in the Drug Manufacturers industry
Industry Median: 7.47 vs BOM:524742: 21.76

Caplin Point Laboratories Net Cash per Share Historical Data

The historical data trend for Caplin Point Laboratories's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caplin Point Laboratories Net Cash per Share Chart

Caplin Point Laboratories Annual Data
Trend Jun15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.64 35.49 49.46 54.50 59.86

Caplin Point Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.50 - 51.11 - 59.86

Competitive Comparison of Caplin Point Laboratories's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caplin Point Laboratories's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Caplin Point Laboratories's Price-to-Net-Cash falls into.



Caplin Point Laboratories Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Caplin Point Laboratories's Net Cash per Share for the fiscal year that ended in Mar. 2024 is calculated as

Net Cash per Share (A: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(8362.6-3505.6-311.2)/75.9417
=59.86

Caplin Point Laboratories's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

Net Cash per Share (Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(8362.6-3505.6-311.2)/75.9417
=59.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Caplin Point Laboratories  (BOM:524742) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Caplin Point Laboratories Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Caplin Point Laboratories's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Caplin Point Laboratories (BOM:524742) Business Description

Traded in Other Exchanges
Address
Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is the India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, liquid orals, dry powder, soft gels, penems injections, suppositories. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops. The business of the company is organized into the following product segments, Antibiotics, Nsaids, Ophthalmics, Pain Management, and Antiulcers. Its products have a presence in the Latin American and African markets.

Caplin Point Laboratories (BOM:524742) Headlines

No Headlines